Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$18.09 USD
-0.28 (-1.52%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.09 USD
-0.28 (-1.52%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $18.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of 1.77% and 2.10%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 15th
by Zacks Equity Research
BWB, CDE, ONEM, RCUS, and TMHC have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2021
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -41.56% and -48.67%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Arcus Biosciences, Inc. (RCUS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences, Inc. (RCUS) Stock Jumps 15.5%: Will It Continue to Soar?
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -52.11% and -49.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcus Biosciences, Inc. (RCUS) Stock Jumps 9.5%: Will It Continue to Soar?
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.
Affimed (AFMD) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
bluebird (BLUE) to Spin Off Oncology Unit Into Separate Entity
by Zacks Equity Research
bluebird (BLUE) to separate its severe genetic disease and oncology businesses into different and independent publicly traded companies. Shares up.
Moleculin Biotech (MBRX) Jumps: Stock Rises 8.5%
by Zacks Equity Research
Moleculin Biotech (MBRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Zosano Pharma (ZSAN) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Zosano Pharma (ZSAN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Exact Sciences (EXAS) Soars: Stock Adds 9.8% in Session
by Zacks Equity Research
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Are Options Traders Betting on a Big Move in Arcus Biosciences (RCUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
Infinity's Eganelisib Gets Fast Track Tag for Breast Cancer
by Zacks Equity Research
Infinity's (INFI) eganelisib, combined with a checkpoint inhibitor and chemotherapy, gets Fast Track designation by the FDA for the treatment of inoperable locally-advanced or metastatic TNBC in the first-line setting.
Gilead Expands Collaboration With Tango for Cancer Therapies
by Zacks Equity Research
Gilead (GILD) expands its partnership with biotech company, Tango, for innovative targeted immune evasion cancer therapies.
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Has Arcus Biosciences (RCUS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (RCUS) Outperforming Other Medical Stocks This Year?
Is Arcus Biosciences (RCUS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (RCUS) Outperforming Other Medical Stocks This Year?
Gilead's Rating Upgraded on Potential Coronavirus Drug Sales
by Zacks Equity Research
Gilead (GILD) rides high on potential sales from its experimental coronavirus treatment, remdesivir, and collaboration with Arcus.
Arcus Biosciences (RCUS) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs
by Zacks Equity Research
Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.
Infinity (INFI) Q1 Earnings Lag Estimates, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the first quarter of 2020.
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?